JP2006503904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503904A5 JP2006503904A5 JP2005500014A JP2005500014A JP2006503904A5 JP 2006503904 A5 JP2006503904 A5 JP 2006503904A5 JP 2005500014 A JP2005500014 A JP 2005500014A JP 2005500014 A JP2005500014 A JP 2005500014A JP 2006503904 A5 JP2006503904 A5 JP 2006503904A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- oligonucleotide
- composition according
- hsp27
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 229920000272 Oligonucleotide Polymers 0.000 claims 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 3
- 108020004459 Small Interfering RNA Proteins 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000002924 silencing RNA Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 101700080605 NUC1 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 101700006494 nucA Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (13)
- 治療用作用因子にさらされたｈｓｐ２７発現細胞中で活性型ｈｓｐ２７の量を低下させるのに有効な前記治療用作用因子を含む組成物。
- 前記組成物が、ｈｓｐ２７に特異的な配列であるオリゴヌクレオチドを含む、請求項１記載の組成物。
- 前記オリゴヌクレオチドが、配列番号９１の一部に相補的である配列を有する、請求項２記載の組成物。
- 前記オリゴヌクレオチドが、アンチセンスオリゴヌクレオチドである、請求項２又は３に記載の組成物。
- 前記アンチセンスオリゴヌクレオチドが、１２〜３５ヌクレオチドの長さである、請求項４記載の組成物。
- 前記アンチセンスオリゴヌクレオチドが、配列番号１〜８２のいずれかに示す配列を有する連続した一連の塩基を含む、請求項４又は５に記載の組成物。
- 前記組成物が、ｈｓｐ２７に特異的な配列であるｓｉＲＮＡを含む、請求項２又は３に記載の組成物。
- 前記ｓｉＲＮＡが、１６〜４９ヌクレオチドの長さである、請求項７記載の組成物。
- 前記ｓｉＲＮＡが、配列番号８３〜９０のいずれかに示す連続した一連の塩基を含む、請求項７又は８に記載の組成物。
- 前記オリゴヌクレオチドが、イン・ビボでのヌクレアーゼ消化に対する耐性をもたらす主鎖修飾を有する、請求項２〜９のいずれか一項に記載の組成物。
- 癌の治療に使用するための請求項１〜１０のいずれか一項に記載の組成物。
- 前記癌が、前立腺癌、膀胱癌、肺癌、乳癌、膵癌、大腸癌、皮膚癌（例えば黒色腫）、腎癌又は卵巣癌或いは中枢神経系悪性腫瘍である、請求項１１記載の組成物。
- 注射可能な単位剤形に包装される、請求項１〜１０のいずれか一項に記載の組成物及び製薬上許容される担体を含む薬剤組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41585902P | 2002-10-02 | 2002-10-02 | |
| US60/415,859 | 2002-10-02 | ||
| US46395203P | 2003-04-18 | 2003-04-18 | |
| US60/463,952 | 2003-04-18 | ||
| PCT/CA2003/001588 WO2004030660A2 (en) | 2002-10-02 | 2003-10-02 | Compositions for treatment of prostate and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010155315A Division JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503904A JP2006503904A (ja) | 2006-02-02 |
| JP2006503904A5 true JP2006503904A5 (ja) | 2006-09-28 |
| JP5127138B2 JP5127138B2 (ja) | 2013-01-23 |
Family
ID=32073392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005500014A Expired - Fee Related JP5127138B2 (ja) | 2002-10-02 | 2003-10-02 | 前立腺及び他の癌の治療用の組成物及び方法 |
| JP2010155315A Expired - Fee Related JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010155315A Expired - Fee Related JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US7101991B2 (ja) |
| EP (2) | EP2216029A3 (ja) |
| JP (2) | JP5127138B2 (ja) |
| KR (1) | KR101142080B1 (ja) |
| CN (1) | CN1703229B (ja) |
| AT (1) | ATE465743T1 (ja) |
| AU (1) | AU2003278028B2 (ja) |
| CA (1) | CA2498026C (ja) |
| DE (1) | DE60332363D1 (ja) |
| DK (1) | DK1545561T3 (ja) |
| ES (1) | ES2345330T3 (ja) |
| IL (1) | IL167621A (ja) |
| MX (1) | MXPA05003551A (ja) |
| NO (2) | NO338310B1 (ja) |
| NZ (1) | NZ538841A (ja) |
| WO (1) | WO2004030660A2 (ja) |
| ZA (1) | ZA200502603B (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345330T3 (es) | 2002-10-02 | 2010-09-21 | The University Of British Columbia | Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres. |
| WO2006089209A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
| WO2007025229A2 (en) * | 2005-08-25 | 2007-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hsp27 |
| EP1984399A4 (en) * | 2006-02-10 | 2010-03-03 | Univ California | TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS |
| US8242258B2 (en) * | 2006-12-03 | 2012-08-14 | Agilent Technologies, Inc. | Protecting groups for RNA synthesis |
| US9381209B2 (en) * | 2007-03-05 | 2016-07-05 | The University Of British Columbia | Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy |
| JP2010521460A (ja) | 2007-03-12 | 2010-06-24 | アンティジェン・エクスプレス・インコーポレーテッド | 癌免疫療法におけるＩｉ−ＲＮＡｉ関与Ｉｉ抑制 |
| CA2656577A1 (en) * | 2008-04-14 | 2009-10-14 | The University Of British Columbia | Method for evaluation of a cancer |
| AU2009265194A1 (en) | 2008-07-02 | 2010-01-07 | Enzon Pharmaceuticals Inc | RNA antagonists targeting Hsp27 |
| NZ589262A (en) * | 2008-07-18 | 2012-05-25 | Oncogenex Technologies Inc | Antisense formulation |
| WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| KR101217866B1 (ko) * | 2010-08-18 | 2013-01-03 | 한국원자력의학원 | 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법 |
| DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| JP5658696B2 (ja) * | 2011-02-25 | 2015-01-28 | 株式会社ファンケル | 皮膚のストレス蓄積度の評価方法 |
| CA2747509C (en) | 2011-05-12 | 2017-07-18 | Oncogenex Technologies Inc. | Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors |
| EP2809325A4 (en) * | 2012-02-02 | 2015-04-01 | Univ British Columbia | CANCER POLYTHERAPY USES HSP27 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS OR ANTIFOLATES |
| GB201204785D0 (en) | 2012-03-19 | 2012-05-02 | Queen Mary & Westfield College | Method for determining prognosis of prostate cancer in a subject |
| KR101374585B1 (ko) * | 2012-05-02 | 2014-03-17 | 연세대학교 산학협력단 | ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ |
| CN104781271B (zh) | 2012-08-20 | 2018-07-06 | 加利福尼亚大学董事会 | 具有生物可逆的基团的多核苷酸 |
| WO2016016267A1 (de) | 2014-07-28 | 2016-02-04 | Technische Universität Dresden | Effiziente hemmung von hsp27 |
| BR112018011045A2 (pt) | 2015-11-30 | 2018-11-21 | Univ British Columbia | inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08504766A (ja) * | 1992-12-14 | 1996-05-21 | スタート テクノロジー パートナーシップ | ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与 |
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| JPH09176011A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤 |
| US20060008448A1 (en) * | 1996-06-11 | 2006-01-12 | Minzhen Xu | Inhibition of li expression in mammalian cells |
| JPH107559A (ja) | 1996-06-18 | 1998-01-13 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤 |
| US5962262A (en) * | 1997-07-25 | 1999-10-05 | Incyte Pharmaceuticals, Inc. | Human heat shock 27 like protein |
| US6703228B1 (en) | 1998-09-25 | 2004-03-09 | Massachusetts Institute Of Technology | Methods and products related to genotyping and DNA analysis |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CA2375467C (en) | 1999-07-19 | 2013-10-29 | The University Of British Columbia | Antisense therapy for hormone-regulated tumors |
| AU2001249317A1 (en) * | 2000-03-21 | 2001-10-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| ES2432225T3 (es) * | 2001-08-23 | 2013-12-02 | Arizona Board Of Regents | Reactivos y procedimientos para terapias del músculo liso |
| ES2345330T3 (es) | 2002-10-02 | 2010-09-21 | The University Of British Columbia | Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres. |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2007025229A2 (en) * | 2005-08-25 | 2007-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hsp27 |
| US9381209B2 (en) | 2007-03-05 | 2016-07-05 | The University Of British Columbia | Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy |
-
2003
- 2003-10-02 ES ES03769111T patent/ES2345330T3/es not_active Expired - Lifetime
- 2003-10-02 CA CA2498026A patent/CA2498026C/en not_active Expired - Fee Related
- 2003-10-02 EP EP20100002560 patent/EP2216029A3/en not_active Withdrawn
- 2003-10-02 US US10/605,498 patent/US7101991B2/en not_active Expired - Fee Related
- 2003-10-02 EP EP03769111A patent/EP1545561B1/en not_active Expired - Lifetime
- 2003-10-02 MX MXPA05003551A patent/MXPA05003551A/es active IP Right Grant
- 2003-10-02 NZ NZ538841A patent/NZ538841A/en not_active IP Right Cessation
- 2003-10-02 AT AT03769111T patent/ATE465743T1/de active
- 2003-10-02 CN CN2003801009272A patent/CN1703229B/zh not_active Expired - Fee Related
- 2003-10-02 JP JP2005500014A patent/JP5127138B2/ja not_active Expired - Fee Related
- 2003-10-02 WO PCT/CA2003/001588 patent/WO2004030660A2/en active Application Filing
- 2003-10-02 DK DK03769111.0T patent/DK1545561T3/da active
- 2003-10-02 KR KR1020057005572A patent/KR101142080B1/ko not_active IP Right Cessation
- 2003-10-02 DE DE60332363T patent/DE60332363D1/de not_active Expired - Lifetime
- 2003-10-02 AU AU2003278028A patent/AU2003278028B2/en not_active Ceased
-
2005
- 2005-03-23 IL IL167621A patent/IL167621A/en active IP Right Grant
- 2005-03-31 ZA ZA200502603A patent/ZA200502603B/en unknown
- 2005-04-27 NO NO20052055A patent/NO338310B1/no not_active IP Right Cessation
- 2005-10-28 US US11/262,388 patent/US7723312B2/en not_active Expired - Fee Related
-
2006
- 2006-06-06 US US11/422,481 patent/US7550580B2/en not_active Expired - Fee Related
-
2007
- 2007-11-30 US US11/948,195 patent/US8772470B1/en not_active Expired - Fee Related
-
2009
- 2009-04-01 US US12/416,305 patent/US7847091B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155315A patent/JP5237996B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-27 US US14/288,030 patent/US9085769B2/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/699,360 patent/US9404109B2/en not_active Expired - Fee Related
-
2016
- 2016-04-20 NO NO20160655A patent/NO20160655A1/no not_active Application Discontinuation
- 2016-06-27 US US15/193,369 patent/US9580712B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503904A5 (ja) | ||
| Banelli et al. | MicroRNA in glioblastoma: an overview | |
| Tolcher | Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer | |
| NO20160655A1 (no) | Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| MX2007003795A (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| JP2002539265A5 (ja) | ||
| JP2012085642A5 (ja) | ||
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| HUP0200093A2 (en) | Trpm-2 antisense therapy | |
| JP2005530486A5 (ja) | ||
| WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
| JP2008520591A5 (ja) | ||
| Pradeep et al. | Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics | |
| WO2003030832A3 (en) | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer | |
| Kausch et al. | Antisense oligonucleotide therapy in urology | |
| TW200504210A (en) | A nucleolin antisense inhibiting growth of cancer cell | |
| WO2005028617A3 (en) | Antisense inhibition of laminin-8 expression to inhibit human gliomas | |
| Santhosh et al. | Ovarian solid tumors: current treatment and recent developments using stimuli-responsive polymers: a systemic review | |
| AU2021413862A1 (en) | Template directed immunomodulation for cancer therapy | |
| JP2007517498A5 (ja) | ||
| WO2020153503A1 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| PL1618195T3 (pl) | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe | |
| Rubenstein et al. | Treatment of MCF-7 breast cancer cells employing mono-and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2 |